Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

OBJECTIVE: To evaluate the safety and efficacy of a chimeric monoclonal antibody to tumor necrosis factor alpha (TNF alpha) in the treatment of patients with rheumatoid arthritis (RA). METHODS: Twenty patients with active RA were treated with 20 mg/kg of anti-TNF alpha in an open phase I/II trial la...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser: Elliott, M, Maini, R, Feldmann, M, Long-Fox, A, Charles, P, Katsikis, P, Brennan, F, Walker, J, Bijl, H, Ghrayeb, J
Format: Journal article
Sprache:English
Veröffentlicht: 1993
_version_ 1826278307305357312
author Elliott, M
Maini, R
Feldmann, M
Long-Fox, A
Charles, P
Katsikis, P
Brennan, F
Walker, J
Bijl, H
Ghrayeb, J
author_facet Elliott, M
Maini, R
Feldmann, M
Long-Fox, A
Charles, P
Katsikis, P
Brennan, F
Walker, J
Bijl, H
Ghrayeb, J
author_sort Elliott, M
collection OXFORD
description OBJECTIVE: To evaluate the safety and efficacy of a chimeric monoclonal antibody to tumor necrosis factor alpha (TNF alpha) in the treatment of patients with rheumatoid arthritis (RA). METHODS: Twenty patients with active RA were treated with 20 mg/kg of anti-TNF alpha in an open phase I/II trial lasting 8 weeks. RESULTS: The treatment was well tolerated, with no serious adverse events. Significant improvements were seen in the Ritchie Articular Index, which fell from a median of 28 at study entry to a median of 6 by week 6 (P < 0.001), the swollen joint count, which fell from 18 to 5 (P < 0.001) over the same period, and in the other major clinical assessments. Serum C-reactive protein levels fell from a median of 39.5 mg/liter at study entry to 8 mg/liter at week 6 (P < 0.001), and significant decreases were also seen in serum amyloid A and interleukin-6 levels. CONCLUSION: Treatment with anti-TNF alpha was safe and well tolerated and resulted in significant clinical and laboratory improvements. These preliminary results support the hypothesis that TNF alpha is an important regulator in RA, and suggest that it may be a useful new therapeutic target in this disease.
first_indexed 2024-03-06T23:41:59Z
format Journal article
id oxford-uuid:6fa117ba-1ac7-403d-a11c-3d7322975ec0
institution University of Oxford
language English
last_indexed 2024-03-06T23:41:59Z
publishDate 1993
record_format dspace
spelling oxford-uuid:6fa117ba-1ac7-403d-a11c-3d7322975ec02022-03-26T19:31:52ZTreatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6fa117ba-1ac7-403d-a11c-3d7322975ec0EnglishSymplectic Elements at Oxford1993Elliott, MMaini, RFeldmann, MLong-Fox, ACharles, PKatsikis, PBrennan, FWalker, JBijl, HGhrayeb, JOBJECTIVE: To evaluate the safety and efficacy of a chimeric monoclonal antibody to tumor necrosis factor alpha (TNF alpha) in the treatment of patients with rheumatoid arthritis (RA). METHODS: Twenty patients with active RA were treated with 20 mg/kg of anti-TNF alpha in an open phase I/II trial lasting 8 weeks. RESULTS: The treatment was well tolerated, with no serious adverse events. Significant improvements were seen in the Ritchie Articular Index, which fell from a median of 28 at study entry to a median of 6 by week 6 (P < 0.001), the swollen joint count, which fell from 18 to 5 (P < 0.001) over the same period, and in the other major clinical assessments. Serum C-reactive protein levels fell from a median of 39.5 mg/liter at study entry to 8 mg/liter at week 6 (P < 0.001), and significant decreases were also seen in serum amyloid A and interleukin-6 levels. CONCLUSION: Treatment with anti-TNF alpha was safe and well tolerated and resulted in significant clinical and laboratory improvements. These preliminary results support the hypothesis that TNF alpha is an important regulator in RA, and suggest that it may be a useful new therapeutic target in this disease.
spellingShingle Elliott, M
Maini, R
Feldmann, M
Long-Fox, A
Charles, P
Katsikis, P
Brennan, F
Walker, J
Bijl, H
Ghrayeb, J
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
title Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
title_full Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
title_fullStr Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
title_full_unstemmed Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
title_short Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
title_sort treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
work_keys_str_mv AT elliottm treatmentofrheumatoidarthritiswithchimericmonoclonalantibodiestotumornecrosisfactoralpha
AT mainir treatmentofrheumatoidarthritiswithchimericmonoclonalantibodiestotumornecrosisfactoralpha
AT feldmannm treatmentofrheumatoidarthritiswithchimericmonoclonalantibodiestotumornecrosisfactoralpha
AT longfoxa treatmentofrheumatoidarthritiswithchimericmonoclonalantibodiestotumornecrosisfactoralpha
AT charlesp treatmentofrheumatoidarthritiswithchimericmonoclonalantibodiestotumornecrosisfactoralpha
AT katsikisp treatmentofrheumatoidarthritiswithchimericmonoclonalantibodiestotumornecrosisfactoralpha
AT brennanf treatmentofrheumatoidarthritiswithchimericmonoclonalantibodiestotumornecrosisfactoralpha
AT walkerj treatmentofrheumatoidarthritiswithchimericmonoclonalantibodiestotumornecrosisfactoralpha
AT bijlh treatmentofrheumatoidarthritiswithchimericmonoclonalantibodiestotumornecrosisfactoralpha
AT ghrayebj treatmentofrheumatoidarthritiswithchimericmonoclonalantibodiestotumornecrosisfactoralpha